Case Report Section
Paper co-edited with the European LeukemiaNet

Unbalanced rearrangement, der(9;18)(p10;q10) in a patient with myelodysplastic syndrome: Case 0002M

Kavita S Reddy
Kaiser Permanente Southern California, 4580 ElectronicPlace, Los Angeles, CA 90039, USA (KSR)

Published in Atlas Database: March 2011
Online updated version : http://AtlasGeneticsOncology.org/Reports/der918Case2ReddyID100053.html
DOI: 10.4267/2042/46060
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics

Age and sex
85 years old male patient.

Previous history

Organomegaly
No hepatomegaly, no splenomegaly, no enlarged lymph nodes, no central nervous system involvement.

Blood

WBC : 1.9X 10^9/l
HB : 10.9g/dl
Platelets : 57X 10^9/l

Cyto-Pathology Classification

Cytology
MDS (normocellular marrow with dysmegakaryopoiesis and dysgranulopoiesis; consistent with myelodysplastic syndrome)

Immunophenotype: NA
Rearranged Ig Tcr: NA
Diagnosis: MDS

Survival

Date of diagnosis: 03-2005
Treatment: not on any treatment
Complete remission : None
Treatment related death : NA
Relapse : no
Phenotype at relapse: NA
Status: Alive. Last follow up: 12-2010
Survival: 66 months.

Karyotype

Culture time : 24 and 72 hours with overnight Colcemid
Banding: GTW at 400 bands
Results
3/2005 BM 45,X,-Y[5]/46,XY,+9, der(9;18)(p10;q10)[11]/46,XY[4];
6/2007 BM 45,X,-Y[5]/46,XY[16];
12/2010 BM 46,XY,+9, der(9;18)(p10;q10)[15]/46,XY[5]
Karyotype at Relapse: NA
Other molecular cytogenetics technics: None
Unbalanced rearrangement, der(9;18)(p10;q10) in a patient with myelodysplastic syndrome. Case 0002M.

Reddy KS

Comments

Both the cases described in this study were followed for >5 years. Case 0001M, had thrombocytosis and could not tolerate Interferon or Hydrea treatment and hence was treated with Busulfan. The patient was positive for JAK2 mutation (on chromosome 9). A recent study was to rule out transformation of MPN as there was myelofibrosis, splenomegaly and apparent progression of the disease. The der(9;18) was first identified in the stem line and a sideline had partial deletion of chromosome 13q. Case 0002M was a MDS case with a der(9;18) detected in the initial study and again when the patient was suspected to be transforming >5 years later. This patient had very little symptoms and was not treated.

In this report for the first time a long standing MDS case was found to have the der(9;18) at initial diagnosis and after over 5 years. Others reported with der(9;18)(n 7) had PV (n 3) or post PV myelofibrosis (n 4) and one had sAML after ET. The JAK2V617F is a gain in function mutation on chromosome 9. Hence, the extra copy of 9p may exacerbate the MPN as observed in 0001M case. The patient had splenomegaly and also myelofibrosis when the patient was found with the der(9;18). Der(9;18) is the sole abnormality in most reported cases, balanced translocations or complex aberrant karyotypes were reported as additional abnormalities. Our patient had del(13) in a sideline and this abnormality is observed in MPN. Among the 9 patients with der(9;18) two arose post treatment (present case 0001M and Andrieux et al 2003), and the other were at diagnosis.

The der(9;18) supports progression of the disease in case 0001M but in case 0002M with MDS it reappears when there is suspicion of transformation and its role is less uncertain.

References


This article should be referenced as such:


Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10)